Background/Objectives: Generous consumption of phytonutrient-rich foods, including blueberries, provides benefits to multiple physiologic and metabolic systems. This study explored the potential that regular, generous blueberry intake could favorably modulate fecal microbiome composition in sedentary older (>60 years) men and women with overweight or obesity (BMI ≥ 25 to 32 kg/m2). Methods: Participants (n = 55) were randomized to daily consumption of either lyophilized blueberry powder (equivalent to 1.5 cups of blueberries) or an indistinguishable placebo powder; both groups participated in weekly supervised exercise classes. Fecal samples were collected at 0 and 12 weeks and frozen. Following this, 16S rRNA gene sequencing was used to profile each participant’s fecal microbiome. Blood biomarkers of cardiometabolic health were measured via nuclear magnetic resonance spectroscopy (NMR) pre- and post-treatment. Results: Comparing the baseline and endpoint results for the blueberry (n = 15) and placebo (n = 19) groups, there were no significant overall compositional differences or differences in the level of diversity in the fecal microbiome. However, in subjects whose diet included blueberry powder, there was a significant enrichment (p = 0.049) in the relative abundance of Coriobacteriales incertae sedis, a taxonomic group of bacteria that facilitates the metabolism of dietary polyphenols. The placebo group exhibited significant reductions in total cholesterol, LDL-C, non-HDL-C, total LDL-P, large LDL-P, and ApoB, while the blueberry group exhibited significant reductions in total HDL-P and ApoA-I after 12 weeks compared to baseline. Conclusions: Generous blueberry consumption may upregulate the ability of the older human gut to utilize dietary polyphenols by altering the fecal microbiome. Longer, larger-scale studies with blueberries or blueberry powder are needed to observe improvements in cardiometabolic risk factors in older adults with overweight or obesity.
The microbiota has proved to be one of the critical factors for many diseases, and researchers have been using microbiome data for disease prediction. However, models trained on one independent microbiome study may not be easily applicable to other independent studies due to the high level of variability in microbiome data. In this study, we developed a method for improving the generalizability and interpretability of machine learning models for predicting three different diseases (colorectal cancer, Crohn’s disease, and immunotherapy response) using nine independent microbiome datasets. Our method involves combining a smaller dataset with a larger dataset, and we found that using at least 25% of the target samples in the source data resulted in improved model performance. We determined random forest as our top model and employed feature selection to identify common and important taxa for disease prediction across the different studies. Our results suggest that this leveraging scheme is a promising approach for improving the accuracy and interpretability of machine learning models for predicting diseases based on microbiome data.
While the COVID-19 pandemic presents a global challenge, the U.S. response places substantial responsibility for both decision-making and communication on local health authorities. To better support counties and municipalities, we integrated baseline data on relevant community vulnerabilities with dynamic data on local infection rates and interventions into a Pandemic Vulnerability Index (PVI). The PVI presents a visual synthesis of county-level vulnerability indicators that can be compared in a regional, state, or nationwide context. We describe use of the PVI, supporting epidemiological modeling and machine-learning forecasts, and deployment of an interactive, web Dashboard. The Dashboard facilitates decision-making and communication among government officials, scientists, community leaders, and the public to enable more effective and coordinated action to combat the pandemic. One Sentence Summary: The COVID-19 Pandemic Vulnerability Index Dashboard monitors multiple data streams to communicate county-level trends and vulnerabilities and support local decision-making to combat the pandemic.
The 2022 global Mpox outbreak swiftly introduced unforeseen diversity in the monkeypox virus (MPXV) population, resulting in numerous Clade IIb sublineages. This propagation of new MPXV mutations warrants the thorough re-investigation of previously recommended or validated primers designed to target MPXV genomes. In this study, we explored 18 PCR primer sets and examined their binding specificity against 5210 MPXV genomes, representing all the established MPXV lineages. Our results indicated that only five primer sets resulted in almost all perfect matches against the targeted MPXV lineages, and the remaining primer sets all contained 1–2 mismatches against almost all the MPXV lineages. We further investigated the mismatched primer-genome pairs and discovered that some of the primers overlapped with poorly sequenced and assembled regions of the MPXV genomes, which are consistent across multiple lineages. However, we identified 173 99% genome-wide conserved regions across all 5210 MPXV genomes, representing 30 lineages/clades with at least 80% lineage-specific consensus for future primer development and primer binding evaluation. This exercise is crucial to ensure that the current detection schemes are robust and serve as a framework for primer evaluation in clinical testing development for other infectious diseases.
Bacterial vaginosis (BV) is a type of vaginal inflammation caused by bacterial overgrowth, upsetting the healthy microbiome of the vagina. Existing clinical testing for BV is primarily based upon physical and microscopic examination of vaginal secretions. Modern PCR-based clinical tests target panels of BV-associated microbes, such as the Labcorp NuSwab test that targets Atopobium ( Fannyhessea ) vaginae , Megasphaera-1 , and Bacterial Vaginosis Associated Bacterium (BVAB)−2 . Remnant clinician-collected NuSwab vaginal swabs underwent DNA extraction and 16S V3–V4 rRNA gene sequencing to profile microbes in addition to those included in the Labcorp NuSwab test. Community state types (CSTs) were determined using the most abundant taxon detected in each sample. PCR results for NuSwab panel microbial targets were compared against the corresponding microbiome profiles. Metabolic pathway abundances were characterized via metagenomic prediction from amplicon sequence variants (ASVs). 16S V3–V4 rRNA gene sequencing of 75 remnant vaginal swabs yielded 492 unique 16S V3–V4 ASVs, identifying 83 unique genera. NuSwab microbe quantification was strongly concordant with quantification by sequencing ( P < 0.01). Samples in CST-I (18 of 18, 100%), CST-II (three of three, 100%), CST-III (15 of 17, 88%), and CST-V (one of one, 100%) were largely categorized as BV-negative via the NuSwab panel, while most CST-IV samples (28 of 36, 78%) were BV-positive or BV-indeterminate. BV-associated microbial and predicted metabolic signatures were shared across multiple CSTs. These findings highlight robust sequencing-based quantification of Labcorp NuSwab BV microbes, accurate discrimination of vaginal microbiome CSTs dominated by distinct Lactobacilli , and expanded the identification of BV-associated bacterial and metabolic biomarkers. IMPORTANCE: Bacterial vaginosis (BV) poses a significant health burden for women during reproductive years and onward. Current BV diagnostics rely on either panels of select microbes or on physical and microscopic evaluations by technicians. Here, we sequenced the microbiome profiles of samples previously diagnosed by the Labcorp NuSwab test to better understand disruptions to the vaginal microbiome during BV. We show that microbial sequencing can faithfully reproduce targeted PCR diagnostic results and can improve our knowledge of healthy and BV-associated microbial and metabolic biomarkers. This work highlights a robust, agnostic BV classification scheme with potential for future development of sequencing-based BV diagnostic tools.
The nasopharyngeal microbiome plays an essential role in respiratory health and disease, making it a key focus of metagenomic research. However, inconsistent reporting standards across studies hinder reproducibility, usability, and integration of these data, limiting the scientific value of nasopharyngeal metagenomic datasets. This systematic review assessed the impact of non-standardized reporting on metagenomic studies, focusing on reproducibility, usability, and integration in publicly available datasets. We screened 988 studies pertaining to research on the nasopharyngeal microbiome. Of the screened manuscripts, 227 were selected for full-text review based on detailed inclusion and exclusion criteria. Key findings included that only 78 studies (34%) had reproducible methods sections, 33 of those 78 studies (15%) provided analytically sufficient metadata, and 4% demonstrated mismatched laboratory methods incompatible with reported datasets. We attributed these inconsistencies to gaps in methodological transparency, lack of accessible metadata, and misaligned file formats, which collectively impede dataset reuse and integration. The interchangeability of nasopharyngeal aspirates (NPA) and nasopharyngeal swabs (NPS) was evaluated using reproducible datasets. Significant variation in the microbial profile between source types was confirmed, highlighting that specimen interchange would be inappropriate within a study. Our results underscore the critical need for standardized reporting guidelines in metagenomic research to improve data transparency, facilitate reproducibility, and enable broader data integration. The adoption of comprehensive and consistent reporting practices would significantly enhance the scientific utility of nasopharyngeal microbiome studies, promoting reliable, replicable, and integrative research across the field.